High-definition transcranial direct current stimulation (HD-tDCS) as augmentation therapy in late-life depression (LLD) with suboptimal response to treatment-a study protocol for a double-blinded randomized sham-controlled trial.

Autor: Ngan STJ; New Clinical Building, Queen Mary Hospital, 2/F, 102 Pok Fu Lam Road, Pok Fu Lam, Hong Kong, Hong Kong., Chan LK; Department of Psychiatry, Kwai Chung Hospital, Kwai Chung, Hong Kong, Hong Kong., Chan WC; New Clinical Building, Queen Mary Hospital, 2/F, 102 Pok Fu Lam Road, Pok Fu Lam, Hong Kong, Hong Kong., Lam LCW; Department of Psychiatry, Tai Po Hospital, G/F, Multi-Centre, Tai Po, Hong Kong, Hong Kong., Li WK; New Clinical Building, Queen Mary Hospital, 2/F, 102 Pok Fu Lam Road, Pok Fu Lam, Hong Kong, Hong Kong., Lim K; Department of Psychiatry, University of Minnesota Medical School, Minneapolis, MN, USA., Or E; New Clinical Building, Queen Mary Hospital, 2/F, 102 Pok Fu Lam Road, Pok Fu Lam, Hong Kong, Hong Kong., Pang PF; Department of Psychiatry, United Christian Hospital, Kwun Tong, Hong Kong, Hong Kong., Poon TK; Department of Psychiatry, Kowloon Hospital, Kadoorie Hill, Hong Kong, Hong Kong., Wong MCM; Department of Psychiatry, United Christian Hospital, Kwun Tong, Hong Kong, Hong Kong., Wu YKA; Department of Psychiatry, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong, Hong Kong., Cheng PWC; New Clinical Building, Queen Mary Hospital, 2/F, 102 Pok Fu Lam Road, Pok Fu Lam, Hong Kong, Hong Kong. chengpsy@hku.hk.
Jazyk: angličtina
Zdroj: Trials [Trials] 2022 Oct 28; Vol. 23 (1), pp. 914. Date of Electronic Publication: 2022 Oct 28.
DOI: 10.1186/s13063-022-06855-z
Abstrakt: Background: Late-life depression (LLD) has a poorer prognosis and higher relapse rate than younger adults, with up to one third of patients with LLD showing suboptimal response to antidepressant therapy. LLD has been associated with significant impairment in cognition and daily functioning. Few studies have evaluated the therapeutic effects of high-definition transcranial direct current stimulation (HD-tDCS) on depressive and cognitive symptoms of LLD. The current randomized controlled trial assesses the efficacy of HD-tDCS as an augmentation therapy with antidepressants compared to sham-control in subjects with LLD.
Methods: Fifty-eight patients with LLD will be recruited and randomly assigned to the active HD-tDCS or sham HD-tDCS group. In both groups, patients will receive the active or sham intervention in addition to their pre-existing antidepressant therapy, for 2 weeks with 5 sessions per week, each lasting 30 min. The primary outcome measures will be the change of depressive symptoms, clinical response and the remission rate as measured with the Hamilton Depression Rating scale (HAMD-17) before and after the intervention, and at the 4th and 12th week after the completed intervention. Secondary outcome measures include cognitive symptoms, anxiety symptoms, daily functioning and adverse effects.  DISCUSSION: Older adults with depression are associated with poorer outcomes or unsatisfactory responses to antidepressant therapy, and significant cognitive decline. Therefore, a new effective treatment option is needed. This randomized control trial aims at assessing the efficacy of HD-tDCS on ameliorating the depressive, cognitive and anxiety symptoms, and improving the daily functioning of subjects with LLD.
Trial Registration: ClinicalTrials.gov NCT05322863. Registered on 11 April 2022.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje